---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-004730"
form_type: "8-K"
ticker: "PVCT"
cik: "0000315545"
company_name: "PROVECTUS BIOPHARMACEUTICALS, INC."
filed_at: "2026-02-02T23:59:59+00:00"
generated_at: "2026-05-16T05:47:27.232954+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Provectus extends automatic conversion date for Series D and D-1 preferred stock to Dec 2028

## Summary
- Automatic conversion date for Series D and D-1 preferred stock extended from June 20, 2026 to December 31, 2028.
- Amendments apply to Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock, both par value $0.001.
- Board of directors and a special committee of independent directors approved the amendments.
- No changes to conversion terms other than the extension of the conversion date.

## SEC filing metadata
- accession: 0001493152-26-004730
- form_type: 8-K
- ticker: PVCT
- cik: 0000315545
- company_name: PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at: 2026-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315226004730/0001493152-26-004730-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315226004730/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-004730
- JSON: https://secwatch.observer/filing/0001493152-26-004730.json
- Plain text: https://secwatch.observer/filing/0001493152-26-004730.txt

## Source-grounded claims
- claim_id: 873e6e2bf78e5340e8aedc46031192cff877bcde
  claim: PROVECTUS BIOPHARMACEUTICALS, INC.: Extended the automatic conversion date of Series D and Series D-1 Convertible Preferred Stock from June 20, 2026 to December 31, 2028 (effective 2026-01-30).
  evidence_excerpt: On January 30, 2026, Provectus Biopharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock (the “Series D Amendment”) and a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock (the “Series D-1 Amendment,” and together with the Series D Amendment, the “Amendments”) with the Secretary of State of the State of Delaware.
  evidence_url: https://www.sec.gov/Archives/edgar/data/315545/000149315226004730/0001493152-26-004730-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.